ID: ALA5198190

Max Phase: Preclinical

Molecular Formula: C18H21NO5

Molecular Weight: 331.37

Associated Items:

Representations

Canonical SMILES:  COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(OC)c1

Standard InChI:  InChI=1S/C18H21NO5/c1-10-14(17(20)23-4)16(12-7-6-8-13(9-12)22-3)15(11(2)19-10)18(21)24-5/h6-9,16,19H,1-5H3

Standard InChI Key:  UVZJDLNWYRQSSL-UHFFFAOYSA-N

Associated Targets(Human)

Phosphodiesterase 1C 228 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 331.37Molecular Weight (Monoisotopic): 331.1420AlogP: 2.28#Rotatable Bonds: 4
Polar Surface Area: 73.86Molecular Species: NEUTRALHBA: 6HBD: 1
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: CX LogP: 1.72CX LogD: 1.72
Aromatic Rings: 1Heavy Atoms: 24QED Weighted: 0.85Np Likeness Score: -0.47

References

1. Huang MX, Tian YJ, Han C, Liu RD, Xie X, Yuan Y, Yang YY, Li Z, Chen J, Luo HB, Wu Y..  (2022)  Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects.,  65  (12.0): [PMID:35666471] [10.1021/acs.jmedchem.2c00458]

Source